India Pharmaceutical Market Reflection Report covers market overview, company watch, product performance and theraphy areas.

1. 0
Market Reflection
Report
March 2015

2. 1
IPM overview
Market Reflection Report March 2015
TSA IPM Trends SSA IPM Trends
 IPM was valued at Rs. 90,346 crs and the retail sector was valued at Rs. 76,482 crs as of MAT Mar’15 with CAGR growth of 11%
during the period 2012-15
 Anti-infectives, Cardiac and Gastro Intestinal remains the leading therapeutic categories accounting for 36% of IPM
 Indian companies continue to drive growth in the market with Sun catapulted to the top of the league, after its merger deal with
Ranbaxy fructified, as forecasted by IMS Health in Jan ‘15
 Acute therapies dominates the market constituting 70% of IPM
MonthGrowth%
Value Rs. crs
Growth
SPLY
90,346
80,566
73,096
66,054
7,4646,4145,8615,446
+16%
+12%
2015201420132012
76,482
67,709
61,394
55,577
6,2815,3954,8844,551
+16%
+13%
2015201420132012
MonthMAT
20
15
10
5
0
25
DecNovOctSepAugJulJunMayAprMarFebJan
25
20
0
10
5
15
DecNovOctSepAugJulJunMayAprMarFebJan
2013
2015
2014

3. 2
Top 150 companies snapshot
• Lupin moved up among the top 10 companies as a result of the merger of Ranbaxy with Sun; the market share of
the top 10 companies increased from 40% of IPM in Feb ’15 to 43% in Mar ’15 on MAT and month basis
• The top 150 companies continue to account for 97% of IPM on MAT and month basis
Source: IMS Health TSA, Mar ‘15
IPM value – Rs.7,464 crs (16% Growth)
Month Mar ‘15
IPM value – Rs.90,346 crs (12% Growth)
MAT Mar ‘15
249
494
488
381
830
Value (Rs. Crs)
Rank #101 - 150
Rank #61 - 100
Rank #41 - 60
Rank #31 - 40
Rank #21 - 30
Rank #11 - 20 1,623
Rank #1 - 10 3,193
3
7
7
5
11
22
43
% MS
9
14
18
14
18
21
15
% Gwth Value (Rs. Crs)
3,087
6,029
5,901
4,762
9,976
19,244
38,851
3
7
7
5
11
21
43
% MS
8
12
18
12
11
13
12
% Gwth
Market Reflection Report March 2015

4. 3
Top companies #1-10
 TSA: Macleods registered significant growth greater than 20% both on MAT and month basis.
 SSA: Intas registered double the growth % of IPM during the month while Macleods and Mankind registered
significant growth greater than 20% both on MAT and month basis Source: IMS Health TSA & SSA, Mar ‘15
250
254
261
269
382
470
618
Value
(Rs. Crs)
Lupin Limited 214
Pfizer 226
Macleods Pharma 248
Alkem
GlaxoSmithKline
Zydus Cadila
Mankind
Cipla
Abbott
Sun
17
11
26
19
10
7
24
19
12
11
% Gwth
2.9
3.0
3.3
3.4
3.4
3.5
3.6
5.1
6.3
8.3
% MS
179
181
204
217
218
220
240
302
401
524
Value
(Rs. Crs)
Intas Pharma
Lupin Limited
GlaxoSmithKline
Macleods Pharma
Zydus Cadila
Alkem
Mankind
Cipla
Abbott
Sun
32
18
11
27
8
21
24
18
11
12
% Gwth
2.8
2.9
3.3
3.5
3.5
3.5
3.8
4.8
6.4
8.3
% MS
Month
Value
(Rs. Crs)
Lupin Limited 2,581
Pfizer 2,745
Macleods Pharma 2,933
GlaxoSmithKline 3,088
Alkem 3,113
Mankind 3,171
Zydus Cadila 3,181
Cipla 4,760
Abbott 5,742
Sun 7,538
15
9
23
5
11
19
3
20
8
10
% Gwth
2.9
3.0
3.3
3.4
3.5
3.5
3.5
5.3
6.4
8.3
% MS
Value
(Rs. Crs)
Lupin Limited 2,173
Pfizer 2,218
GlaxoSmithKline 2,523
Macleods Pharma 2,556
Zydus Cadila 2,667
Alkem 2,717
Mankind 2,825
Cipla 3,777
Abbott 4,974
Sun 6,398
16
8
8
25
4
12
20
16
8
11
% Gwth
2.8
2.9
3.3
3.3
3.5
3.6
3.7
4.9
6.5
8.4
% MS
MAT
SSA
TSA
Market Reflection Report March 2015

5. 4
Top companies #11-20
• TSA –The majority of companies in this bucket posted significant growth greater 20% than during the month
• SSA –Similarly, Dr. Reddys, Aristo, Torrent and Alembic posted strong retail growth greater than 20% during the
month Source: IMS Health TSA & SSA, Mar ‘15
149
167
169
175
176
182
209
Value
(Rs. Crs)
Micro Labs 122
Alembic 125
Glenmark Pharma 147
U S V
Sanofi
Emcure
Dr Reddys Labs
Aristo Pharma
Torrent Pharma
Intas Pharma
12
24
20
14
16
8
28
28
24
33
% Gwth
1.6
1.7
2.0
2.0
2.2
2.3
2.4
2.4
2.4
2.8
% MS
104
113
123
128
135
144
146
156
160
177
Value
(Rs. Crs)
Micro Labs
Alembic
Sanofi
Glenmark Pharma
U S V
Emcure
Dr Reddys Labs
Aristo Pharma
Torrent Pharma
Pfizer
15
24
10
19
15
9
30
28
25
9
% Gwth
1.7
1.8
2.0
2.0
2.2
2.3
2.3
2.5
2.6
2.8
% MS
Value
(Rs. Crs)
Alembic 1,494
Micro Labs 1,517
U S V 1,746
Glenmark Pharma 1,781
Dr Reddys Labs 1,949
Aristo Pharma 2,019
Sanofi 2,061
Emcure 2,126
Torrent Pharma 2,170
Intas Pharma 2,381
14
7
9
19
13
15
5
12
11
21
% Gwth
1.7
1.7
1.9
2.0
2.2
2.2
2.3
2.4
2.4
2.6
% MS
Value
(Rs. Crs)
Micro Labs 1,284
Alembic 1,354
Sanofi 1,544
Glenmark Pharma 1,551
U S V 1,577
Dr Reddys Labs 1,651
Emcure 1,777
Aristo Pharma 1,796
Torrent Pharma 1,902
Intas Pharma 2,037
9
15
11
19
10
17
13
16
12
21
% Gwth
1.7
1.8
2.0
2.0
2.1
2.2
2.3
2.4
2.5
2.7
% MS
SSA
TSA
MonthMAT
Market Reflection Report March 2015

6. 5
Top companies #21-30
• TSA – Wockhardt and Ipca registered double the IPM growth during the month
• SSA –Wockhardt, Ipca, Indoco and Cadila registered significant growth of 20% during the month
Source: IMS Health TSA & SSA, Mar ‘15
70
78
79
91
106
109
121
55
61
61
Value
(Rs. Crs)
Indoco
Franco Indian
Merck Limited
Cadila Pharma
MSD Pharma
Unichem
FDC
Novartis Intl.
Ipca Labs
Wockhardt Ltd
20
12
8
28
9
11
15
6
32
37
% Gwth
0.7
0.8
0.8
0.9
1.0
1.1
1.2
1.4
1.5
1.6
% MS
49
54
57
58
60
72
84
93
96
99
Value
(Rs. Crs)
Indoco
Merck Limited
Franco Indian
Cadila Pharma
MSD Pharma
Unichem
FDC
Novartis Intl.
Ipca Labs
Wockhardt Ltd
21
11
11
25
7
12
16
6
35
27
% Gwth
0.8
0.9
0.9
0.9
1.0
1.1
1.3
1.5
1.5
1.6
% MS
668
733
777
850
959
Value
(Rs. Crs)
Indoco
Franco Indian
Merck Limited
Cadila Pharma
MSD Pharma
Unichem 1,006
FDC 1,060
Wockhardt Ltd 1,284
Ipca Labs 1,303
Novartis Intl. 1,336
11
10
9
15
8
8
8
14
20
3
% Gwth
0.7
0.8
0.9
0.9
1.1
1.1
1.2
1.4
1.4
1.5
% MS
604
686
689
724
757
913
982
Value
(Rs. Crs)
Indoco
Merck Limited
Franco Indian
Cadila Pharma
MSD Pharma
Unichem
FDC
Wockhardt Ltd 1,101
Ipca Labs 1,139
Novartis Intl. 1,164
12
10
10
15
9
8
8
10
22
3
% Gwth
0.8
0.9
0.9
1.0
1.0
1.2
1.3
1.4
1.5
1.5
% MS
SSA
TSA
MonthMAT

7. 6
Highlights
TSA
Movers & Shakers TSA: Companies
In the month of March’15(in comparison to
Feb’15), among the top 25 companies
 Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.28 %.
 Aristo Pharma has gained 4 ranks and moved to
13th position.
 Glaxosmithkline has gained 3 ranks and moved
to 6th position.
 Dr Reddys Labs & USV have gained 2 ranks
and moved to 14th & 17th position respectively.
As per March’15 MAT (in comparison to
Feb’15) among the top 25 companies
 Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.34 %.
 Companies below Ranbaxy have gained 1 rank
post Sun-Ranbaxy merger.
SSA
Movers & Shakers SSA: Companies
In the month of March-15 (in comparison to
February-15 month), among the TOP 25
companies
 Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.34 %.
 Alkem & Lupin have gained 3 ranks each &
occupied 5th & 9th position respectively.
 Dr Reddys Labs & USV have gained 2 ranks
each & occupied 14th & 16th position
respectively.
 Intas gained 1 rank to occupy the 10th position
As per March-15 MAT (in comparison to
February-15 MAT), among the TOP 25
companies
 Sun Pharma has moved 2 ranks to achieve top
position in the IPM with market share of 8.36 %.
 Aristo Pharma & Glenmark have gained 2 ranks
each & occupied 13th & 17th position
respectively.
Market Reflection Report March 2015

8. 7
NLEM/Non-NLEM
ValueVolume
 NLEM impacted drugs constituted 15% of IPM in value terms with a growth of 10.4% as of MAT Mar ‘15 over same
period last year (SPLY)
 The share of the non-NLEM drugs was 76% of IPM in volume terms for the month of Mar’15
Source: IMS Health TSA, Mar ‘15
SPLY Previous month
Mar '14 Mar '15 Value Growth
(%)
Feb '15 Mar '15
Value Growth (%)
Rs. (crs) Rs. (crs) Rs. (crs) Rs. (crs)
NLEM 989.1 1091.9 10.4 1119.2 1091.9 -2.4
Non-NLEM 5424.5 6371.7 17.5 6439.7 6371.7 -1.1
IPM 6413.6 7463.6 16.4 7558.8 7463.6 -1.3
SPLY Previous month
Mar '14 Mar '15
Volume Growth
(% )
Feb '15 Mar '15
Volume Growth
(%)Units (‘000) Units (‘000) Units (‘000) Units (‘000)
NLEM 380800 399972 5.0 406526 399972 -1.6
Non-NLEM 1184052 1298946 9.7 1322253 1298946 -1.8
IPM 1564851 1698918 8.6 1728779 1698918 -1.7
Market Reflection Report March 2015

9. 8
Indian /MNC trends
• Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of
18.6% over Mar’14
• MNCs registered a growth of 10.4% as against the IPM growth of 16.4% during the month
Source: IMS Health TSA, Mar ‘15
0
5
10
15
20
25
Apr ’14
IPM
Mar ’15Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14
% Gwth over same month last year
Jun ’14May ’14 Jul ’14 Aug ’14
MNC
Indian
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
Value (Rs. Crs)
MNC
Apr ’14 Jul ’14 Aug ’14 Sep ’14 Oct ’14 Nov ’14 Dec ’14 Jan ’15 Mar ’15Feb ’15
Indian
IPM
Jun ’14May ’14
MonthGrowthValue
Market Reflection Report March 2015

10. 9
Acute/Chronic trends
 Acute therapies continue to dominate the market accounting for 70% of the market during the month
 Chronic therapies registered growth of 15%, while acute therapies posted growth of 17% in Mar ‘15
 Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 30% during the
month Source: IMS Health TSA, Mar ‘15
5
10
15
20
25
Apr ’14 Mar ’15Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14Aug ’14Jul ’14Jun ’14May ’14
8788
108118
155
Amoxy. & Clav. SolidsFood SupplementsGlim+MetforminDPP4 inhibitors & CombCough Preps Ethical
30.37 20.40 17.63 -5.05 23.03
9
16
19
Franco Indian
Wockhardt Ltd
Glenmark Pharma
19
26
27
U S V
Novartis Intl.
MSD Pharma
10
11
23
Lupin Limited
Sun
U S V
13
14
15
Nutricia Internat
Abbott
Apex
14
14
17
Mankind
Alkem
GlaxoSmithKline
Top5TC4sTop3Cos.inTC4
Growth (%)
Value (Rs.
Crs)
Value (Rs. Crs)
Growth(%)
Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs)
ChronicAcuteIPM
Market Reflection Report March 2015

11. 10
Top 40 brands
 Abbott, Alkem and GlaxoSmithKline have the highest number of brands among the top 40 at 5 each
 The vaccine Synflorix (GlaxoSmithKline) registered outstanding growth of 83% during the month
 Thyronorm (Abbott), Spasmo-Proxyvon + (Wockhardt) and Shelcal (Torrent Pharma) posted impressive growth
greater than 40% in Mar ’15 over the same month last year
22
23
23
23
26
28
38
20
20
21
Value
(Rs. Crs)
Voveran (Novartis Intl.)
Phensedyl Cough (Abbott)
Clavam (Alkem)
Thyronorm (Abbott)
Glycomet-GP (U S V)
Monocef (Aristo Pharma)
Prevenar-13 (Pfizer)
Corex (Pfizer)
Augmentin (GlaxoSmithKline)
Mixtard (Abbott)
29
8
25
47
18
36
38
16
21
11
% Gwth % MS
0.26
0.27
0.28
0.29
0.30
0.31
0.31
0.35
0.38
0.51
14
15
15
15
15
15
16
16
16
17
Value
(Rs. Crs)
Pan (Alkem)
Moxikind-CV (Mankind)
Calpol (GlaxoSmithKline)
Zincovit (Apex)
Becosules (Pfizer)
Zifi (FDC)
Foracort (Cipla)
Shelcal (Torrent Pharma)
Liv-52 (Himalaya Drug)
Alburel (Reliance Lifescie.)
17
28
27
11
13
37
20
40
7
26
% Gwth % MS
0.19
0.20
0.20
0.20
0.20
0.21
0.21
0.21
0.22
0.22
17
18
18
18
18
19
19
19
19
20
Value
(Rs. Crs)
Janumet (MSD Pharma)
Betadine (Win Medicare)
Lantus (Sanofi)
Galvus Met (Novartis Intl.)
Synflorix (GlaxoSmithKline)
Novomix (Abbott)
Panderm+ (Macleods Pharma)
Spasmo-Proxyvon + (Wockhardt)
Dexorange (Franco Indian)
Volini (Sun)
20
8
7
17
83
18
37
45
4
6
% Gwth % MS
0.23
0.24
0.24
0.24
0.24
0.25
0.26
0.26
0.26
0.26
12
13
13
13
13
13
14
14
14
14
Value
(Rs. Crs)
Pan-D (Alkem)
Aciloc (Cadila Pharma)
Taxim (Alkem)
Zinetac (GlaxoSmithKline)
Eltroxin (GlaxoSmithKline)
Azithral (Alembic)
Budecort (Cipla)
Taxim-O (Alkem)
Duphaston (Abbott)
Electral (FDC)
25
13
14
0
10
30
38
18
13
18
% Gwth % MS
0.16
0.17
0.17
0.17
0.17
0.18
0.19
0.19
0.19
0.19
Top1-10Top11-20
Top21-30Top31-40
Source: IMS Health TSA, Mar ‘15
Market Reflection Report March 2015

12. 11
Star Brands of the month
TSA
Movers & Shakers TSA: Products
Among the Top 25 Products as per Mar’15 MAT (in comparison to Feb’15 MAT)
 Mixtard is the No 1 brand.
 Thyronorm and Voveran has gained 2 ranks each to occupy 6th and 14th position respectively.
 Aciloc has gained 4 ranks to occupy 25th position.
 Shelcal has gained 1 rank to occupy 23rd position.
Among the Top 25 products as per March’15 month (in comparison to Feb’15 month)
 Mixtard is the No 1 brand.
 Synflorix has gained 24 ranks to occupy 16th position.
 Spasmo-Proxyvon + has gained 6 ranks to occupy 13th position.
 Dexorange and Zifi have gained 5 ranks each to occupy 12th and 25th position respectively.
 Prevenar-13, Monocef & Alburel have gained 4 ranks each to occupy 4th, 5th and 21st position respectively.
 Shelcal has gained 3 ranks each to occupy 23rd position.
 Volini has gained 2 ranks to occupy 11th position.
 Phensedyl Cough & Voveran have gained 1 rank each to occupy 9th & 10th position respectively.
Market Reflection Report March 2015

13. 12
Gastro Intestinal
1,066
IPM 7,464
774
866
535
589
591
Cardiac
Respiratory
Anti Diabetic
630
Pain / Analgesics
Anti-infectives
Vaccines 178
Others 240
Gynaec. 416
Neuro / CNS 450
Derma 456
Vitamins / Minerals / Nutrients 7
6
2
3
6
6
8
8
8
10
12
14
100
36
11
22
11
15
17
18
15
21
17
13
20
16
0
8
2
-1
-2
2
1
-1
-9
0
-1
-4
-1
Gwth % (SPLY) Gwth% (Prev. Mth)
Therapy trends
• Vaccines continues to record remarkable value growth of 36% as of MAT Mar ’15
• Anti-infectives constitute the largest market share of 14%, with significant growth on MAT basis
Source: IMS Health TSA, Mar ‘15
Value (Rs Crs) MS %
Market Reflection Report March 2015

14. 13
Top Therapy Trends
Source: IMS Health TSA, Mar ‘15
29
30
33
33
42
44
48
54
57
95
Value
(Rs. Crs)
Amikacin
Cefuroxime Oral Solids
Meropenem
Piperacillin+Tazobactam
Cefpodoxime Solids
Azithromycin Oral Solids
Amoxy. & Clav. Liquids
Cefixime Oral Sol.
Ceftriaxone Injectabls
Amoxy. & Clav. Solids
28
16
7
22
30
27
39
16
30
28
% Gwth (SPLY)
18
24
29
29
31
32
33
40
43
66
Value
(Rs. Crs)
Losartan+ Hydrochlorthiaz
Amlodipine+Telmisartan
Amlodipine
Enoxaparin
Telmisartan + Hct
Atenolol+Amlodipine
Metoprolol
Telmisartan
Rosuvastatin
Atorvastatin
5
26
9
6
11
15
12
22
23
14
% Gwth (SPLY)
Anti-Infective
21
22
23
24
27
29
38
39
43
47
Value
(Rs. Crs)
Digest. Inc. Enzyme Liqui
Rabeprazole
Omepraz.+ Domperid.
Antacid+Antiflatu.Liq
Others
Oral Electrolytes
Pantoprazole Solids
Ranitidine Oral Solids
Rabepra.+ Domperid.
Pantopr.+ Domperid.
26
13
14
20
23
47
15
14
24
25
% Gwth (SPLY)
14
15
18
21
30
31
40
42
67
176
Value
(Rs. Crs)
Levocetirizine
Salbutamol+Ipratropium
Budesonide
Salmeterol+Fluticasone
Cold Prep. Solids
Formoteral+Budesonide
Levocetiriz.+Montelu Sold
Cold Prep. Liquids
Codeine And Comb.
Cough Prep. Ethicals
21
28
42
17
24
23
26
23
8
35
% Gwth (SPLY)
Cardiac
GI
Respiratory
• Oral Electrolytes, Budesonide, Amoxy. & Clav. Liquids and Cough Prep. Ethicals registered significant growth greater
than 34% over the same period last year
Market Reflection Report March 2015

15. 14
Glossary
Abbreviation Description/Definition
IPM Indian Pharmaceutical Market
MAT Moving Annual Total
CAGR Compound Annual Growth Rate
TSA Total Sales Audit
SSA Secondary Sales Audit
Gwth Growth
MS Market Share
Rs Rupees
NLEM National List of Essential Medicines
SPLY Same Period Late Year
MNC Multi-National Company
DPP Dipeptidyl Peptidase 4
TC Therapeutic Category
Crore / crs 10 million
Market Reflection Report March 2015

16. 15
About IMS Health
World’s leading provider of healthcare consulting, technology, and informatics
 Founded in 1954
 Operates in over 100 countries; employs 10,000+ people
world wide
 Data from 100,000 suppliers and insights of more than 40
billion healthcare transactions
 1200+ experts resources, 3000+ service resources and
5000+ clients
 Operational in India for more than 11 years, with over 2000
employees with offices in Gurgaon, Mumbai, Delhi &
Bangalore
PUBLIC HEALTH
 Policyreformsand advocacy
 Enabling evidence based publichealth
decisions
 Health infrastructure development
 Health resourcesplanning and
allocation
 Monitoring &evaluation
 Designing and implementation support
 Strengthening health caresupply
chain
 Enabling TechnologySolutions
 Product& Portfolio strategy
 Entry& Growth Strategy
 Brand and Commercial Strategy
 Pricing and marketaccess
 Launch and commercial Excellence
 Performance management
 Transaction AdvisoryServicesand
Due Diligence
 Drug salesdatabase(global and local)
 Census - Physicians,Chemists,
Hospitals,Doctor, etc
PHARMA & ALLIED HEALTH
 Networkexpansion and management
 Doctorselection
 Pharma &Providerengagement
strategy
 Diseasemanagement
 Claimsdatabase
 Claimsanalytics– benchmarksand
costs
 Patientlevel information
 Health technologyassessment
PAYERS PROVIDERS
 Providerdatabases
 Hospital performance transformation
programs
 Performance benchmarking
 Expansion &Growth strategy
 Feasibilityanalysisand businessplan
development
 Brownfield hospital acquisition
 Financial modeling,funding modalities
and transaction advisory
 BI Solutionsforhospitals
OUR SERVICE OFFERINGS
95 process patents
worldwide in life sciences processes
Ranked 2nd Life Science
Technology Vendors for 2013 (IT
Services) by IDC
World’s most admired
companies FORTUNE Magazine
2008 and 2010
PHARMA AND LIFE-SCIENCES

17. 16
Disclaimer
 The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats,
and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the
completeness or accuracy of such third party sources or data.
 IMS Health captures 90% of the retail sector and 65% of the hospital sector through individual audits, the Stockist Sell-Out Audit (SSA) and Hospital
Secondary Audit (HSA), as well as the dispensing doctors sector as part of the Total Sales Audit (TSA) from 2007 onwards. The combined audited
sectors accounted for an estimated 87.4% of the total pharmaceutical market in 2014.
 As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks
and uncertainties, and are not to be considered guarantees of any particular outcome.
 It should neither be regarded as comprehensive nor sufficient for making decisions, nor should it be used in place of professional advice. IMS Health
accepts no responsibility for any loss arising from any action taken or not taken by anyone using this material.
 All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by
any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of
IMS HEALTH.
 ©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.